Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Masive middle cerebral artery infarct; Consciousness disturbed; severe left hemiparesis; COMIRNATY subcutaneous; This is a spontaneous report from a non-contactable consumer downloaded from the Regulatory Authority, regulatory authority number DE-PEI-CADR2021015226. An 88-year-old male patient received BNT162B2 (COMIRNATY, Solution for injection), subcutaneously at an unspecified age on 14Jan2021 (lot number: EJ6797, expiration date unknown) at single dose for covid-19 immunisation. Medical history included atrial fibrillation and arrhythmia, both ongoing. The patient''s concomitant medications were not reported. The patient previously took rivaroxaban from 12Jan2001 to 14Jan2021 for anticoagulation drug level increased. On 24Jan2021 the patient experienced masive middle cerebral artery infarct, consciousness disturbed, severe left hemiparesis. The outcome of event masive middle cerebral artery infarct was fatal. The patient died on 04Feb2021. The outcome of the other events was unknown. It was not reported if an autopsy was performed. Sender Comment: Absolute arrhythmia in atrial fibrillation. Oral anticoagulation with rivaroxaban from 12Jan2021 to 14Jan2021 paused / acute media infarction on the right with impaired consciousness and severe hemiparesis on the left. No follow-up attempts are possible. No further information is expected.; Reported Cause(s) of Death: Masive middle cerebral artery infarct
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166